Literature DB >> 1682696

Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia.

R P Gale1, A Butturini.   

Abstract

Maintenance chemotherapy with 6-mercaptopurine and methotrexate, widely believed an essential contribution to the high cure rates achieved in children with acute lymphoblastic leukaemia (ALL), is thought to work by killing the leukaemia cells that remain after intensive chemotherapy. We suggest instead that ALL commonly arises in precursor B cells normally programmed to die, and that maintenance chemotherapy does not kill these cells but controls growth of the leukaemia clone so that programmed death can occur. A similar approach may apply to other cancers in which programmed death is intrinsic to the normal counterparts of the neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682696     DOI: 10.1016/0140-6736(91)92604-z

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

Review 1.  Chemotherapy of childhood lymphoblastic leukaemia: the first 50 years.

Authors:  J Lilleyman
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

Review 2.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  The study of minimal residual disease in acute lymphoblastic leukaemia.

Authors:  C J Knechtli; N J Goulden; K Langlands; M N Potter
Journal:  Clin Mol Pathol       Date:  1995-04

4.  Non-compliance with oral chemotherapy in childhood leukaemia.

Authors:  J S Lilleyman; L Lennard
Journal:  BMJ       Date:  1996-11-16

5.  Phenotyping and genotyping studies of thiopurine S-methyltransferase in Kazaks.

Authors:  Hong Wei; Shufeng Zhou; Chengrong Li; Jianping Zhang; Jueheng Wu; Min Huang
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

6.  Maintenance treatment and shared care in lymphoblastic leukaemia.

Authors:  J M Chessells
Journal:  Arch Dis Child       Date:  1995-10       Impact factor: 3.791

7.  A grounded theory of the process of adherence to oral chemotherapy in Hispanic and caucasian children and adolescents with acute lymphoblastic leukemia.

Authors:  Wendy Landier; Cynthia B Hughes; Evelyn R Calvillo; Nancy L R Anderson; Deborah Briseño-Toomey; Leticia Dominguez; Alex M Martinez; Cara Hanby; Smita Bhatia
Journal:  J Pediatr Oncol Nurs       Date:  2011-06-08       Impact factor: 1.636

8.  Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?

Authors:  Shenmiao Yang; Neil E Kay; Min Shi; Curtis A Hanson; Robert Peter Gale
Journal:  Leukemia       Date:  2022-09-13       Impact factor: 12.883

9.  Late immune recovery in children treated for malignant diseases.

Authors:  Gabor T Kovacs; Olga Barany; Barbara Schlick; Monika Csoka; Judit Gado; Andrea Ponyi; Judit Müller; Julia Nemeth; Peter Hauser; Daniel J Erdelyi
Journal:  Pathol Oncol Res       Date:  2008-06-25       Impact factor: 3.201

10.  Thiopurine methyltransferase genotyping in Palestinian childhood acute lymphoblastic leukemia patients.

Authors:  Basim Mohammad Ayesh; Wael Mohammad Harb; Abdalla Assaf Abed
Journal:  BMC Hematol       Date:  2013-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.